Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update
Rigel Pharmaceuticals (Nasdaq: RIGL) has scheduled its first quarter 2025 financial results announcement and business update for Tuesday, May 6, 2025, after market close. The company will host a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Investors can join the call through two options:
- Phone: 877-407-3088 (domestic) or 201-389-0927 (international)
- Webcast: Available through the Investor Relations section at www.rigel.com
Rigel, founded in 1996 and based in South San Francisco, is a biotechnology company focused on developing therapies for hematologic disorders and cancer. The webcast will be archived and accessible for replay through the company website for 90 days following the call.
Rigel Pharmaceuticals (Nasdaq: RIGL) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 e l'aggiornamento aziendale per martedì 6 maggio 2025, dopo la chiusura dei mercati. La società terrà una conference call e una trasmissione in diretta alle 16:30 ora Eastern (13:30 ora Pacific).
Gli investitori possono partecipare alla chiamata tramite due modalità:
- Telefono: 877-407-3088 (nazionale) o 201-389-0927 (internazionale)
- Webcast: disponibile nella sezione Investor Relations su www.rigel.com
Rigel, fondata nel 1996 e con sede a South San Francisco, è una azienda biotecnologica specializzata nello sviluppo di terapie per disturbi ematologici e tumori. La registrazione della trasmissione sarà archiviata e disponibile per la visione in replica sul sito aziendale per 90 giorni dopo la chiamata.
Rigel Pharmaceuticals (Nasdaq: RIGL) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 y una actualización empresarial para el martes 6 de mayo de 2025, después del cierre del mercado. La compañía realizará una conferencia telefónica en vivo y una transmisión web a las 4:30 p.m. hora del Este (1:30 p.m. hora del Pacífico).
Los inversores pueden unirse a la llamada a través de dos opciones:
- Teléfono: 877-407-3088 (nacional) o 201-389-0927 (internacional)
- Webcast: Disponible en la sección de Relaciones con Inversores en www.rigel.com
Rigel, fundada en 1996 y con sede en South San Francisco, es una compañía biotecnológica enfocada en desarrollar terapias para trastornos hematológicos y cáncer. La transmisión quedará archivada y disponible para reproducción en el sitio web de la compañía durante 90 días después de la llamada.
Rigel Pharmaceuticals (나스닥: RIGL)는 2025년 1분기 재무 실적 발표 및 사업 업데이트를 2025년 5월 6일 화요일 장 마감 후에 진행할 예정입니다. 회사는 동부 시간 오후 4시 30분(태평양 시간 오후 1시 30분)에 라이브 컨퍼런스 콜과 웹캐스트를 개최합니다.
투자자들은 다음 두 가지 방법으로 통화에 참여할 수 있습니다:
- 전화: 국내 877-407-3088 또는 국제 201-389-0927
- 웹캐스트: www.rigel.com의 투자자 관계 섹션에서 이용 가능
Rigel은 1996년에 설립되어 South San Francisco에 본사를 둔 생명공학 기업으로, 혈액 질환 및 암 치료제 개발에 주력하고 있습니다. 웹캐스트는 콜 종료 후 90일 동안 회사 웹사이트에서 다시보기로 제공됩니다.
Rigel Pharmaceuticals (Nasdaq : RIGL) a programmé l'annonce de ses résultats financiers du premier trimestre 2025 et une mise à jour commerciale pour le mardi 6 mai 2025, après la clôture des marchés. La société organisera une conférence téléphonique en direct et une diffusion en webcast à 16h30 heure de l'Est (13h30 heure du Pacifique).
Les investisseurs peuvent rejoindre l'appel via deux options :
- Téléphone : 877-407-3088 (domestique) ou 201-389-0927 (international)
- Webcast : disponible dans la section Relations Investisseurs sur www.rigel.com
Rigel, fondée en 1996 et basée à South San Francisco, est une société de biotechnologie spécialisée dans le développement de thérapies pour les troubles hématologiques et le cancer. Le webcast sera archivé et accessible en replay sur le site de la société pendant 90 jours après l'appel.
Rigel Pharmaceuticals (Nasdaq: RIGL) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 und ein Geschäftsupdate für Dienstag, den 6. Mai 2025, nach Börsenschluss geplant. Das Unternehmen wird eine Live-Konferenzschaltung und einen Webcast um 16:30 Uhr Eastern Time (13:30 Uhr Pacific Time) veranstalten.
Investoren können über zwei Optionen an dem Anruf teilnehmen:
- Telefon: 877-407-3088 (national) oder 201-389-0927 (international)
- Webcast: Verfügbar im Bereich Investor Relations auf www.rigel.com
Rigel, gegründet 1996 mit Sitz in South San Francisco, ist ein Biotechnologieunternehmen, das sich auf die Entwicklung von Therapien für hämatologische Erkrankungen und Krebs spezialisiert hat. Der Webcast wird archiviert und für 90 Tage nach dem Anruf auf der Unternehmenswebsite zum Nachsehen bereitgestellt.
- Maintains regular investor communication through scheduled earnings call and webcast
- Provides multiple access methods for investors (phone and webcast)
- 90-day replay availability of the webcast shows transparency
- None.
Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
Phone: 646.461.6387
Email: david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2025-financial-results-and-business-update-302440298.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
When will Rigel (RIGL) report Q1 2025 earnings?
How can investors join Rigel's (RIGL) Q1 2025 earnings call?
Where can I find the replay of Rigel's (RIGL) Q1 2025 earnings webcast?
What is Rigel's (RIGL) main business focus?
How long has Rigel (RIGL) been in business?
